Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | ESR1 | P03372 | 3/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5453551 | 0.95 | TDP1 (0.63) | TDP1CYP3A4ESR1ESR2KDM4E | |
| SCHEMBL18115142 | 0.92 | TDP1 (0.60) | TDP1CYP3A4ESR1ESR2KDM4E | |
| 1,2-Dibromoethane SCHEMBL28837174 | 0.89 | TDP1 (0.71) | TDP1CYP3A4ESR1ESR2KDM4E | |
| SCHEMBL3117767 | 0.86 | TDP1 (0.52) | TDP1CYP3A4ESR1ESR2KDM4E | |
| SCHEMBL20705055 | 0.86 | TDP1 (0.52) | TDP1CYP3A4ESR1ESR2KDM4E | |
| 1-Bromobutane SCHEMBL1614925 | 0.86 | TDP1 (0.52) | TDP1CYP3A4ESR1ESR2KDM4E | |
| Dibromomethane SCHEMBL5329477 | 0.86 | TDP1 (0.75) | TDP1CYP3A4ESR1ESR2KDM4E | |
| Dibromomethane SCHEMBL7950072 | 0.86 | TDP1 (0.75) | TDP1CYP3A4ESR1ESR2KDM4E | |
| SCHEMBL1129619 | 0.84 | TDP1 (0.54) | TDP1CYP3A4ALDH1A1TRPA1TSHR | |
| SCHEMBL4067213 | 0.84 | CYP3A4 (0.50) | TDP1CYP3A4ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5665802-A | REACTING POLYAMIC ACID WITH A DEHYDRATION-CYCLIZATION AGENT, A CATALYST AND AN ORGANIC PHOSPHORUS COMPOUND; EXCELLENT IN TENSILE STRENGTH AND FLEXIBILITY | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1997-09-09 | — | — | US | claimed |
| CN-119708056-A | Multifunctional cardanol polyoxyethylene ether derivative and preparation method and application thereof | 绍兴市富贵花日用品有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-119032090-A | 2-Substituted thiazole HSD17B13 inhibitors and uses thereof | 伊尼制药公司 | 2024-11-26 | — | — | CN | disclosed |
| CN-112010903-B | Organic long afterglow luminous composition | 香港科技大学 | 2023-07-18 | — | — | CN | disclosed |
| CN-111548369-B | Method for simply and conveniently preparing high-purity olopatadine hydrochloride intermediate | 内蒙古京东药业有限公司 | 2023-02-28 | — | — | CN | disclosed |
| CN-114127046-A | Fluorescence system for biological imaging and use thereof | 莱托克斯有限公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-113874381-A | Inhibitors of RAF kinase | 金耐特生物制药公司 | 2021-12-31 | — | — | CN | disclosed |
| US-11034709-B2 | Organic long persistence luminescence compositions | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2021-06-15 | — | — | US | disclosed |
| US-20200377534-A1 | Organic Long Persistence Luminescence Compositions | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2020-12-03 | — | — | US | disclosed |
| CN-112010903-A | Organic long persistence luminescent compositions | 香港科技大学 | 2020-12-01 | — | — | CN | disclosed |
| EP-1317424-A2 | POLYAMINE ANALOGUES AS THERAPEUTIC AND DIAGNOSTIC AGENTS | MediQuest Therapeutics, Inc. (US) | 2003-06-11 | — | — | EP | disclosed |
| US-6337351-B1 | AROMATIC OLEFIN AMINES | TARGACEPT, INC. | 2002-01-08 | — | — | US | disclosed |
| WO-2001092218-A2 | POLYAMINE ANALOGUES AS THERAPEUTIC AND DIAGNOSTIC AGENTS | ORIDIGM CORPORATION (US) | 2001-12-06 | — | — | WO | disclosed |
| EP-1085011-A1 | Novel polyamine analogues as therapeutic and diagnostic agents | ORIDIGM CORPORATION (US) | 2001-03-21 | — | — | EP | disclosed |
| US-6172261-B1 | BIOSYNTHESIS USING CHAIN EXTENSION | ORIDIGM CORPORATION | 2001-01-09 | — | — | US | disclosed |
| EP-1001927-A2 | NOVEL POLYAMINE ANALOGUES AS THERAPEUTIC AND DIAGNOSTIC AGENTS | ORIDIGM CORPORATION (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999003823-A2 | NOVEL POLYAMINE ANALOGUES AS THERAPEUTIC AND DIAGNOSTIC AGENTS | ORIDIGM CORPORATION (US) | 1999-01-28 | — | — | WO | disclosed |
| US-5665802-A | REACTING POLYAMIC ACID WITH A DEHYDRATION-CYCLIZATION AGENT, A CATALYST AND AN ORGANIC PHOSPHORUS COMPOUND; EXCELLENT IN TENSILE STRENGTH AND FLEXIBILITY | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1997-09-09 | — | — | US | disclosed |
| EP-0350958-B1 | Improved polyimide and polyimide film and manufacturing method thereof | KANEGAFUCHI CHEMICAL IND (JP) | 1994-12-21 | — | — | EP | disclosed |
| EP-0350958-A2 | Improved polyimide and polyimide film and manufacturing method thereof | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1990-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377534-A1 | Organic Long Persistence Luminescence Compositions | VEGFA, SOD1, DNMT3A | TDP1 842/4885CYP3A4 597/4885ESR1 158/4885 |
| US-11034709-B2 | Organic long persistence luminescence compositions | VEGFA, SOD1, DNMT3A | TDP1 842/4885CYP3A4 597/4885ESR1 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.